As sterile preparations, lyophilized powder injectables must be manufactured within a sterile environment. Their Sterility Assurance Level (SAL)-typically required to be no greater than 10⁻³-is guaranteed through sterile manufacturing processes such as sterilization by filtration or direct aseptic filling. The sterility assurance level of a production line relies on rigorous system validation measures, including equipment validation, environmental monitoring, and media fill validation.
Potential side effects associated with the use of lyophilized powder products include allergic reactions (such as skin redness, swelling, and itching), dry skin, infections (resulting from improper application), hyperpigmentation, and skin dependency. Should any discomfort arise after use, one should immediately discontinue the product and seek medical attention; furthermore, it is advisable to incorporate moisturizing and sun protection measures into one's routine while using these products.
Instances have been reported in the market where unbranded "lyophilized powder" vials are fraudulently marketed as injectable Type A Botulinum Toxin or similar pharmaceuticals. Upon analysis, these products are found to lack the purported active ingredients and are consequently classified as counterfeit drugs. Additionally, there are cases involving the illicit sale-via unauthorized channels-of imported "lyophilized powder" weight-loss injections that lack the requisite drug approval certificates. Because these products are not subjected to proper cold-chain management during transport and storage, they pose a serious threat to human health.
Regulatory authorities overseeing pharmaceuticals and medical devices maintain strict oversight of lyophilized powder products. Manufacturers may voluntarily initiate product recalls-such as for marketed recombinant humanized collagen lyophilized powders-in response to issues identified during product testing or regarding raw material inputs, thereby mitigating potential risks.